SCOTUS rules biosimilar applicants can provide notice before FDA approval

The Supreme Court in the Sandoz v Amgen biosimilar case has ruled that an injunction is not available under federal law and an applicant may provide notice before obtaining a licence from the FDA. The ruling is a win for Sandoz, but the case was remanded for the Federal Circuit to rule on whether an injunction is still available under state law
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: